Intellia Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

403

Employees403

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

403

Employees403

NTLA Key Statistics

Market cap

1.19B

Market cap1.19B

Price-Earnings ratio

-2.19

Price-Earnings ratio-2.19

Dividend yield

—

Dividend yield—

Average volume

4.59M

Average volume4.59M

High today

$11.80

High today$11.80

Low today

$10.83

Low today$10.83

Open price

$11.52

Open price$11.52

Volume

5.83M

Volume5.83M

52 Week high

$24.16

52 Week high$24.16

52 Week low

$5.90

52 Week low$5.90

NTLA News

Seeking Alpha 6h

Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates

Earnings Call Insights Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates Aug. 07, 2025 8:18 PM ET Intell...

Analyst ratings

75%

of 28 ratings

Buy

75%

Hold

21.4%

Sell

3.6%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.